• Stefano Tamburin, Kristian Borg, Xavier J Caro, Stefano Jann, Alexander J Clark, Francesca Magrinelli, Gen Sobue, Lars Werhagen, Giampietro Zanette, Haruki Koike, Peter J Späth, Angela Vincent, and Andreas Goebel.
• Department of Neurological and Movement Sciences, University of Verona, Verona, Verona, Italy.
• Pain Med. 2014 Jul 1;15(7):1072-82.

BackgroundThe treatment of chronic pain is still unsatisfactory. Despite the availability of different drugs, most patients with chronic pain do not receive satisfactory pain relief or report side effects. Converging evidence implicates involvement of the immune system in the pathogenesis of different types of nociceptive and neuropathic chronic pain.DesignAt a workshop in Liverpool, UK (October 2012), experts presented evidence suggesting immunological involvement in chronic pain and recent data supporting the concept that the established immune-modulating drug, polyvalent immunoglobulin G (IgG), either given intravenously (IVIg) or subcutaneously (SCIg), may reduce pain in some peripheral neuropathies and a range of other pain disorders. Workshop's attendees discussed the practicalities of using IVIg and SCIg in these disorders, including indications, cost-effectiveness, and side effects.ResultsIgG may reduce pain in a range of nociceptive and neuropathic chronic pain conditions, including diabetes mellitus, Sjögren's syndrome, fibromyalgia, complex regional pain syndrome, post-polio syndrome, and pain secondary to pathological autoantibodies.ConclusionsIgG is a promising treatment in several chronic pain conditions. IgG is a relatively safe therapeutic strategy, with uncommon and mild side effects but high costs. Randomized, controlled trials and predictive tests are needed to better support the use of IgG for refractory chronic pain.Wiley Periodicals, Inc.

11 keywords...

hide…